Lv1
90 积分 2023-09-06 加入
免疫检查点抑制剂的研究进展
23天前
已完结
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
2个月前
已完结
Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
2个月前
已完结
Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab
2个月前
已关闭
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
2个月前
已完结
Mechanisms of cutaneous toxicities to EGFR inhibitors
3个月前
已完结
Risk of Selected Dermatological Toxicities in Cancer Patients Treated with MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis
3个月前
已完结
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas
3个月前
已完结
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
3个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
